Product Review: Pure Pharma Fish Oil

Posted On Sep 16 2016 by

#pure pharma # Product Review: Pure Pharma Fish Oil Pure Pharma has created an omega-3 supplement product reflective of the the company s extremely high standards. From the start I noticed something different about Pure Pharma s approach – taking extra steps to make sure the fish caught are in season creating more sustainability is evidence of a company that prides itself on surpassing its customers expectations. Mercury is always a concern when ingesting large amounts of anything fishy, but Pure Pharma has insured significantly low levels by choosing small fish such as anchovies to create they product. Pure Pharma …


AstraZeneca Careers

Posted On Sep 16 2016 by

#pharma job search # Applying for a job at AstraZeneca couldn’t be easier. Simply enter a keyword to search for jobs you are interested in and click the search jobs button to see what opportunities we have available. New Global R D Centre and Corporate H.Q – Cambridge UK We’ve revealed the proposed designs for our new facility on the Cambridge Biomedical Campus. Learn more. Research Opportunity – At the KI/AZ Integrated Cardio Metabolic Centre (ICMC) Karolinska Institutet and AstraZeneca have partnered together to offer this unique opportunity to work in an open academia industry collaboration environment located in Sweden. …


London s Pharmaceutical Industry

Posted On Sep 16 2016 by

#pharmaceutical industries # London’s Pharmaceutical Industry The United Kingdom has a solid pharmaceutical sector that is driven by innovation and by a desire to make a real difference to people’s lives. According to the New York Times, approximately 20 per cent of the world’s best-selling drugs are manufactured in the UK. The British pharmaceutical industry has a particularly strong presence in London, since the country’s capital is known as one of the world’s top centres for innovation and for high-value industries Overview and recent trends of the London pharmaceutical sector The London pharmaceutical industry has been an established economic sector …


VTv Therapeutics IPO Raises $117M For Alzheimer’s, Diabetes Drugs

Posted On Sep 16 2016 by

#transtech pharma # vTv Therapeutics IPO Raises $117M For Alzheimer’s, Diabetes Drugs [Updated 7/30/15, 4:48 pm. See below. ] Drug developer vTv Therapeutics has joined the ranks of biotech companies going public, raising $117 million in an initial public offering mainly financing late-stage clinical trial work on an Alzheimer’s disease drug candidate that Pfizer pursued, then dropped. The High Point, NC-based company offered 7.8 million shares at $15 per share, falling on the low end of the $15 to $17 price range it set last week. In its first day of trading Thursday, VTv (NASDAQ: VTVT ) opened at $14 …


Company Profile

Posted On Sep 16 2016 by

#transtech pharma # vTv Therapeutics LLC (vTv) is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to advance clinical drug candidates discovered with our innovative technology into safe and effective medicines. vTv has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The …


Onyx Pharma Releases Promising Multiple Myeloma Study Results

Posted On Sep 16 2016 by

#onyx pharma # Onyx Pharma Releases ‘Promising’ Multiple Myeloma Study Results Jul 26th 2010 9:00AM Onyx Pharmaceuticals (ONXX ) announced what it called “promising results” from a mid-stage study of its experimental drug carfilzomib in patients with relapsed and refractory multiple myeloma. ONXX shares soared 12% in recent premarket activity. Patients in the trial had been previously treated, but stopped responding to standard treatments. But nearly a quarter (24%) of the patients responded to carfilzomib for a median duration of 7.4 months. While this may not sound like a big advancement, such patients with the blood cancer usually respond to …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout

Posted On Sep 16 2016 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


TransTech Pharma, Inc

Posted On Sep 16 2016 by

#transtech pharma # High Point, North Carolina (January 25, 2008) High Point, NC and Bagsvaerd, Denmark – January 25, 2008 – TransTech Pharma, Inc. and Novo Nordisk A/S announced today that TransTech has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor antagonists, PPARd agonists, and 11βHSD1 inhibitors. After determining in January 2007 to focus all Novo Nordisk research and development resources on the company’s growing pipeline of protein-based pharmaceuticals, the company divested all existing preclinical and …


Amgen to Buy Onyx for $10

Posted On Sep 16 2016 by

#onyx pharma # Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Amgen will pay $125 a share for Onyx’s outstanding stock, the companies said in a statement yesterday. Net of estimated Onyx cash, the deal is worth $9.7 billion. Onyx’s Kyprolis, approved last year for a rare blood cancer, may spur more than $3 billion in revenue by 2021, according to analyst estimates compiled by Bloomberg. …


How to Get a Job in Pharmaceutical Sales

Posted On Sep 15 2016 by

#pharmaceutical rep # How to get a job in pharmaceutical sales Does a job with a good salary, a company car, a flexible schedule, generous bonuses and no boss breathing down your neck sound like a dream come true? It s a reality for pharmaceutical company representatives. But the work isn t pure glamour. It s also intense, highly competitive and sometimes frustrating. Insiders say it s difficult to get your foot in the door with a drug company, and that it s challenging to excel once you ve landed that first sales job. Do you have what it takes …